MX370175B - Formulaciones de compuestos orgánicos. - Google Patents

Formulaciones de compuestos orgánicos.

Info

Publication number
MX370175B
MX370175B MX2015011705A MX2015011705A MX370175B MX 370175 B MX370175 B MX 370175B MX 2015011705 A MX2015011705 A MX 2015011705A MX 2015011705 A MX2015011705 A MX 2015011705A MX 370175 B MX370175 B MX 370175B
Authority
MX
Mexico
Prior art keywords
formulations
organic compounds
pharmaceutically acceptable
relates
present
Prior art date
Application number
MX2015011705A
Other languages
English (en)
Other versions
MX2015011705A (es
Inventor
Kochhar Charu
Quinton Jacques
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015011705A publication Critical patent/MX2015011705A/es
Publication of MX370175B publication Critical patent/MX370175B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12136Balloons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027Type of occlusion
    • A61B17/1204Type of occlusion temporary occlusion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • A61M25/1002Balloon catheters characterised by balloon shape
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205Introduction devices
    • A61B2017/12054Details concerning the detachment of the occluding device from the introduction device
    • A61B2017/12068Details concerning the detachment of the occluding device from the introduction device detachable by heat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205Introduction devices
    • A61B2017/12054Details concerning the detachment of the occluding device from the introduction device
    • A61B2017/12086Details concerning the detachment of the occluding device from the introduction device magnetically detachable

Abstract

La presente invención se refiere a composiciones farmacéuticas sólidas que comprenden el compuesto inhibidor de cinasa de fosfatidil-inositol-3, 4-(trifluoro-metil)-5-(2,6-dimorfolino- pirimidin-4-il)-piridin-2-amina, o una sal farmacéuticamente aceptable de la misma, estearil-fumarato de sodio, y opcionalmente por lo menos un vehículo farmacéuticamente aceptable adicional. La presente invención también se refiere a los procesos para su preparación, y a su uso como medicamentos para el tratamiento de cáncer.
MX2015011705A 2013-03-06 2014-03-04 Formulaciones de compuestos orgánicos. MX370175B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361773492P 2013-03-06 2013-03-06
PCT/IB2014/059424 WO2014136048A1 (en) 2013-03-06 2014-03-04 Formulations of organic compounds

Publications (2)

Publication Number Publication Date
MX2015011705A MX2015011705A (es) 2016-05-18
MX370175B true MX370175B (es) 2019-12-04

Family

ID=50342366

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011705A MX370175B (es) 2013-03-06 2014-03-04 Formulaciones de compuestos orgánicos.

Country Status (29)

Country Link
US (2) US9474534B2 (es)
EP (1) EP2964200B1 (es)
JP (1) JP6313343B2 (es)
KR (1) KR102233757B1 (es)
CN (1) CN105073099B (es)
AR (1) AR095032A1 (es)
AU (1) AU2014224238B2 (es)
BR (1) BR112015021097B1 (es)
CA (1) CA2904032C (es)
CL (1) CL2015002466A1 (es)
EA (1) EA028301B1 (es)
ES (1) ES2634020T3 (es)
HK (1) HK1212244A1 (es)
IL (1) IL240579B (es)
JO (1) JO3256B1 (es)
MA (1) MA38358B1 (es)
MX (1) MX370175B (es)
MY (1) MY174648A (es)
NZ (1) NZ711015A (es)
PE (1) PE20151607A1 (es)
PH (1) PH12015501945A1 (es)
PL (1) PL2964200T3 (es)
PT (1) PT2964200T (es)
SG (1) SG11201506392VA (es)
TN (1) TN2015000386A1 (es)
TW (1) TW201442712A (es)
UA (1) UA114948C2 (es)
WO (1) WO2014136048A1 (es)
ZA (1) ZA201505830B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498604B2 (en) 1997-11-12 2016-11-22 Genesis Technologies Llc Medical device and method
US9561094B2 (en) 2010-07-23 2017-02-07 Nfinium Vascular Technologies, Llc Devices and methods for treating venous diseases
JP2017516584A (ja) 2014-06-04 2017-06-22 エンフィニアム バスキュラー テクノロジーズ, エルエルシー 低半径方向力の脈管デバイスおよび閉塞の方法
TWI804919B (zh) * 2015-06-30 2023-06-11 美商建南德克公司 含藥物之立即釋放錠劑及形成該錠劑的方法
EP4199798A1 (en) * 2020-09-27 2023-06-28 Boston Scientific Scimed Inc. Expandable guide devices, systems, and methods
WO2022170187A1 (en) * 2021-02-05 2022-08-11 Pyne Devaraj Detachable balloon embolization device and methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100459029B1 (ko) * 1995-12-27 2006-03-27 얀센 파마슈티카 엔.브이. 생점착성고체투여형
US5916235A (en) 1997-08-13 1999-06-29 The Regents Of The University Of California Apparatus and method for the use of detachable coils in vascular aneurysms and body cavities
ES2343228T3 (es) * 1998-02-10 2010-07-26 Ethicon Endo-Surgery, Inc. Aparato de oclusion, de anclaje, de tensionado o de direccion por flujo.
US6066157A (en) 1998-09-16 2000-05-23 Medtronics Ave, Inc. Anchor joint for coaxial balloon dilatation catheter
US6368338B1 (en) 1999-03-05 2002-04-09 Board Of Regents, The University Of Texas Occlusion method and apparatus
US7331973B2 (en) 2002-09-30 2008-02-19 Avdanced Cardiovascular Systems, Inc. Guide wire with embolic filtering attachment
US7618435B2 (en) * 2003-03-04 2009-11-17 Nmt Medical, Inc. Magnetic attachment systems
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AU2009288200A1 (en) * 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
IN2012DN03271A (es) * 2009-10-23 2015-10-23 Merck Sharp & Dohme
US8992540B2 (en) 2010-07-22 2015-03-31 Kyphon Sarl Adjustable surgical instruments and methods of use and fabrication
WO2012060847A1 (en) * 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US8641777B2 (en) 2011-06-03 2014-02-04 Reverse Medical Corporation Embolic implant and method of use
WO2014164535A1 (en) 2013-03-11 2014-10-09 Ferry Steven J A guidewire/ partial occluder for intraluminal travel

Also Published As

Publication number Publication date
HK1212244A1 (en) 2016-06-10
JP2016510065A (ja) 2016-04-04
SG11201506392VA (en) 2015-09-29
JP6313343B2 (ja) 2018-04-18
IL240579B (en) 2019-08-29
US10342547B2 (en) 2019-07-09
MY174648A (en) 2020-05-05
EP2964200A1 (en) 2016-01-13
KR20150123248A (ko) 2015-11-03
UA114948C2 (uk) 2017-08-28
CL2015002466A1 (es) 2016-03-04
PH12015501945B1 (en) 2016-01-11
ZA201505830B (en) 2017-07-26
EA201591649A1 (ru) 2016-01-29
US20160015643A1 (en) 2016-01-21
AR095032A1 (es) 2015-09-16
ES2634020T3 (es) 2017-09-26
MA38358B1 (fr) 2017-07-31
WO2014136048A1 (en) 2014-09-12
BR112015021097B1 (pt) 2022-08-30
AU2014224238A1 (en) 2015-09-03
TW201442712A (zh) 2014-11-16
PT2964200T (pt) 2017-07-25
MX2015011705A (es) 2016-05-18
PH12015501945A1 (en) 2016-01-11
US9474534B2 (en) 2016-10-25
TN2015000386A1 (en) 2017-01-03
US20160045202A1 (en) 2016-02-18
CN105073099A (zh) 2015-11-18
NZ711015A (en) 2020-02-28
MA38358A1 (fr) 2016-11-30
CN105073099B (zh) 2018-10-26
CA2904032C (en) 2021-02-16
EP2964200B1 (en) 2017-04-19
KR102233757B1 (ko) 2021-03-30
EA028301B1 (ru) 2017-10-31
IL240579A0 (en) 2015-09-24
CA2904032A1 (en) 2014-09-12
PL2964200T3 (pl) 2017-09-29
JO3256B1 (ar) 2018-09-16
AU2014224238B2 (en) 2016-07-14
PE20151607A1 (es) 2015-11-26
BR112015021097A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
PH12015501945B1 (en) Formulations of organic compounds
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2013011086A (es) (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
PH12015502365A1 (en) Bace1 inhibitors
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
MY193740A (en) "substituted 2,4 diamino-quinoline as new anticancer agents"
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
UA117154C2 (uk) Антагоністи s1p3
EA201692298A1 (ru) Производные карбоксамидов
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
TN2015000524A1 (en) Pharmaceutical compositions
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
MX2015012575A (es) Novedosos derivados de acrilamida como agentes contra la malaria.

Legal Events

Date Code Title Description
FG Grant or registration